What is CJC-1295?

CJC-1295 is a research peptide in the GH Secretagogue class. GHRH analog with extended half-life (DAC variant). It is studied at per-dose ranges of 1–2 mg / week (1–2 mg weekly), administered 1–2× weekly sc over cycles of 12 weeks on / 4 off. Supplied in Thailand by Thailand Peptides — Bangkok-based, research use only.

Modified GHRH(1-29) with DAC extending half-life to ~8 days. Elevates baseline IGF-1.

Published and preclinical data are summarised below; dose ranges shown reflect protocols in the research literature and should be interpreted accordingly.

How does CJC-1295 work?

Primary mechanism: GHRH analog with extended half-life (DAC variant). Research on CJC-1295 implicates downstream effects on related signalling cascades, with magnitude and clinical relevance dependent on dose, timing, and individual pharmacogenomic factors.

Receptor binding affinity and post-receptor signalling for CJC-1295 remain areas of active investigation; several proposed effects within the GH Secretagogue class are currently supported only by in-vitro or rodent data, and should be interpreted accordingly.

CJC-1295 dosage & protocol

Reference protocol for CJC-1295 (research context only, drawn from published literature):

  • Per dose: 1–2 mg / week
  • Weekly total: 1–2 mg
  • Frequency: 1–2× weekly SC
  • Cycle: 12 weeks on / 4 off

Stacking CJC-1295

Commonly referenced pairing with CJC-1295: Ipamorelin. Stacking rationale should be grounded in complementary mechanisms, not additive speculation; interactions at shared receptors or enzymatic pathways should be accounted for. Both compounds in a CJC-1295 stack are supplied by Thailand Peptides on the same order via the Bangkok research desk.

Contraindications

Active malignancy, pregnancy. Additional caution is warranted in individuals with hepatic or renal impairment, endocrine disorders, or concurrent pharmacotherapy affecting the pathways described above.

CJC-1295 — common questions

What is CJC-1295 and what is it used for in research?
CJC-1295 is classified within the GH Secretagogue group. Modified GHRH(1-29) with DAC extending half-life to ~8 days. Elevates baseline IGF-1. Research applications focus on the pathways outlined below. All references on this page describe published research only — CJC-1295 is supplied for in-vitro and laboratory use, not for human consumption.
How does CJC-1295 work?
Primary mechanism: GHRH analog with extended half-life (DAC variant). Downstream effects depend on dose, timing, and the biological system under investigation. Receptor binding and post-receptor signalling for CJC-1295 remain areas of active study, and several proposed effects are supported only by preclinical data.
What is the typical CJC-1295 research dose?
Published research protocols for CJC-1295 describe per-dose ranges of 1–2 mg / week, with a weekly total near 1–2 mg, administered 1–2× weekly sc. Typical cycle: 12 weeks on / 4 off. These ranges reflect the literature and are not dosing recommendations for any individual.
Where can I buy CJC-1295 in Thailand?
CJC-1295 is supplied by Thailand Peptides, a Bangkok-based research-peptide supplier. Orders are placed directly via WhatsApp to the Bangkok research desk — no cart, no account, no forms. Pricing and shipping are provided on request. Open a line with the research desk →
How fast can CJC-1295 be delivered in Thailand?
Same-week delivery across Thailand is standard for orders confirmed within business hours (GMT+7, Monday–Saturday). Bangkok metro deliveries typically arrive within 1–3 business days; other provinces within 3–5. Regional Southeast Asia shipping is available on request.

Citations

  1. Teichman SL, et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295. J Clin Endocrinol Metab. 2006. PMID: 16352683
  2. Ionescu M, et al. Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295, a long-acting GHRH analog. J Clin Endocrinol Metab. 2006. PMID: 17018654

References curated from PubMed. Additional literature summarised in the Thailand Peptides research library.